Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEMD Aethlon Medical	$1.40 -11.9%	$1.33	$1.08 ▼ $8.44	$3.64M	1.72	1.12 million shs	1.75 million shs
DHAI DIH Holding US	$0.28 -1.9%	$0.25	$0.12 ▼ $2.93	$13.26M	0.07	3.34 million shs	1.41 million shs
LYRA Lyra Therapeutics	$6.92 -7.4%	$8.53	$3.81 ▼ $37.50	$11.35M	0.16	283,697 shs	15,282 shs
OSRH OSR	$1.01 +96.1%	$1.00	$0.45 ▼ $13.40	$21.80M	1.49	3.78 million shs	237.08 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEMD Aethlon Medical	0.00%	+39.47%	+19.55%	-50.05%	-66.88%
DHAI DIH Holding US	0.00%	+19.26%	+6.33%	+22.22%	-88.93%
LYRA Lyra Therapeutics	0.00%	+3.99%	-7.79%	+59.72%	-53.60%
OSRH OSR	0.00%	-2.74%	-47.45%	-55.60%	+51,499,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEMD Aethlon Medical	2.9376 of 5 stars	3.0	5.0	0.0	0.0	3.0	0.0	1.3
DHAI DIH Holding US	0.2744 of 5 stars	0.0	3.0	0.0	0.0	0.6	1.7	0.0
LYRA Lyra Therapeutics	3.3256 of 5 stars	3.0	5.0	0.0	0.0	2.1	2.5	1.3
OSRH OSR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEMD Aethlon Medical	2.00	Hold	$56.00	3,900.00% Upside
DHAI DIH Holding US	0.00	N/A	N/A	N/A
LYRA Lyra Therapeutics	2.00	Hold	$100.00	1,345.09% Upside
OSRH OSR	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AEMD, LYRA, DHAI, and OSRH Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/14/2025	AEMD Aethlon Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/14/2025	LYRA Lyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/7/2025	AEMD Aethlon Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEMD Aethlon Medical	$570K	6.39	N/A	N/A	$2.55 per share	0.55
DHAI DIH Holding US	$64.47M	0.21	N/A	N/A	($0.80) per share	-0.35
LYRA Lyra Therapeutics	$1.53M	7.42	N/A	N/A	$8.86 per share	0.78
OSRH OSR	N/A	N/A	N/A	N/A	($3.87) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEMD Aethlon Medical	-$13.39M	-$12.64	N/A	N/A	N/A	N/A	-266.21%	-179.46%	11/12/2025 (Estimated)
DHAI DIH Holding US	-$8.44M	-$0.30	N/A	∞	N/A	-13.59%	N/A	-25.97%	N/A
LYRA Lyra Therapeutics	-$93.43M	-$29.01	N/A	N/A	N/A	-5,043.64%	-404.56%	-60.06%	11/11/2025 (Estimated)
OSRH OSR	-$2.41M	N/A	0.00	∞	N/A	N/A	-12.19%	-8.18%	N/A

Latest AEMD, LYRA, DHAI, and OSRH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	OSRH OSR	N/A	$0.02	N/A	$0.02	N/A	$1.14 million
8/13/2025	Q1 2026	AEMD Aethlon Medical	-$0.68	-$0.85	-$0.17	-$0.85	N/A	N/A
8/12/2025	Q2 2025	LYRA Lyra Therapeutics	-$5.79	-$5.51	+$0.28	-$5.51	$0.18 million	$0.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEMD Aethlon Medical	N/A	N/A	N/A	N/A	N/A
DHAI DIH Holding US	N/A	N/A	N/A	N/A	N/A
LYRA Lyra Therapeutics	N/A	N/A	N/A	N/A	N/A
OSRH OSR	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEMD Aethlon Medical	N/A	2.49	2.49
DHAI DIH Holding US	N/A	0.51	0.34
LYRA Lyra Therapeutics	N/A	2.78	2.78
OSRH OSR	N/A	0.18	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEMD Aethlon Medical	1.99%
DHAI DIH Holding US	27.76%
LYRA Lyra Therapeutics	95.62%
OSRH OSR	55.30%

Insider Ownership

Company	Insider Ownership
AEMD Aethlon Medical	1.20%
DHAI DIH Holding US	49.58%
LYRA Lyra Therapeutics	3.25%
OSRH OSR	33.67%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEMD Aethlon Medical	10	2.60 million	2.57 million	No Data
DHAI DIH Holding US	N/A	47.34 million	23.87 million	N/A
LYRA Lyra Therapeutics	50	1.64 million	1.59 million	Optionable
OSRH OSR	N/A	21.58 million	14.32 million	N/A

AEMD, LYRA, DHAI, and OSRH Headlines

Recent News About These Companies

OSR Holdings Amends Note Purchase Agreement

August 20, 2025 | tipranks.com

Latest OSR Holdings Stock News | NASDAQ:OSRH | Benzinga

August 9, 2025 | benzinga.com

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

August 1, 2025 | prnewswire.com

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share ...

August 1, 2025 | morningstar.comM

OSR Holdings Inc.: OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

August 1, 2025 | finanznachrichten.de

OSR Holdings Reveals Update on Woori IO Deal and Share Exchange

August 1, 2025 | msn.com

OSR Holdings Provides Transparency Update on Equity Financing Instruments

July 31, 2025 | prnewswire.com

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

July 30, 2025 | prnewswire.com

OSR Holdings to acquire South Korea’s medical device company Woori IO

July 28, 2025 | finance.yahoo.com

OSR Holdings enters term sheet to acquire Woori IO (OSRH:NASDAQ)

July 25, 2025 | seekingalpha.com

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in ...

July 25, 2025 | seekingalpha.com

OSR Holdings signs term sheet to acquire noninvasive glucose tech firm

July 25, 2025 | investing.com

OSR Holdings signs term sheet to acquire South Korea-based noninvasive glucose monitoring technology company, Woori IO

July 25, 2025 | pharmabiz.comP

OSR Holdings enters term sheet to acquire Woori IO

July 24, 2025 | msn.com

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

July 24, 2025 | prnewswire.com

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

July 15, 2025 | prnewswire.com

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D ...

July 11, 2025 | taiwannews.com.twT

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG | Morningstar

July 9, 2025 | morningstar.comM

OSR Holdings plans $50 million security token offering in 2025

July 9, 2025 | uk.investing.com

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

July 9, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEMD, LYRA, DHAI, and OSRH Company Descriptions

Aethlon Medical NASDAQ:AEMD

$1.40 -0.19 (-11.95%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 -0.02 (-1.79%)

As of 07:59 PM Eastern

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.

DIH Holding US NASDAQ:DHAI

$0.28 -0.01 (-1.93%)

Closing price 03:59 PM Eastern

Extended Trading

$0.27 -0.01 (-3.21%)

As of 07:56 PM Eastern

DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.

Lyra Therapeutics NASDAQ:LYRA

$6.92 -0.55 (-7.36%)

Closing price 03:59 PM Eastern

Extended Trading

$6.98 +0.05 (+0.79%)

As of 04:10 PM Eastern

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

OSR NASDAQ:OSRH

$1.01 +0.50 (+96.12%)

As of 04:00 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time